Technology Improving Success of Medication-Assisted Treatment in Primary Care

技术提高初级保健药物辅助治疗的成功率

基本信息

批准号：
10212519
负责人：
Steven Paul Jenkins
金额：
$ 83.78万
依托单位：
Q2I, LLC
依托单位国家：
美国
项目类别：
财政年份：
2019
资助国家：
美国
起止时间：
2019-09-30 至 2022-08-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10212519
关键词：
Abstinence Achievement Acquired Immunodeficiency Syndrome Address Adherence Americas Area Artificial Intelligence Behavioral Belief Businesses Caring Cessation of life Clinic Clinical Clinical Management Computer software Continuity of Patient Care Cost Savings Custom Data Development Dropout Drops Education Effectiveness Electronic Health Record Epidemic HIV Interview Investments Length Link Machine Learning Medical Care Team Medicine Methods North America Opiate Addiction Opioid Outcome Outpatients Overdose Patients Persons Pharmaceutical Preparations Phase Primary Health Care Provider Public Health Recovery Relapse Risk Risk Assessment Scientist Services Small Business Technology Transfer Research Specialist Suboxone System Technology Testing Treatment outcome United States Visit Work addiction care providers commercialization cost dashboard design empowered experience follow-up implementation science improved indexing innovation insight iterative design medical specialties medication-assisted treatment mobile application opioid agonist therapy opioid epidemic opioid overdose opioid use opioid use disorder overdose death patient population phase 2 testing primary care setting programs recruit relapse risk scale up social stigma success temporal measurement tool treatment comparison treatment program treatment services user centered design waiver

项目摘要

Project Abstract The opioid epidemic is the U.S.'s most widespread behavioral public health problem, with a higher number of deaths due to drug overdose in 2016 compared to deaths due to HIV at the peak of the AIDS epidemic. Medication assisted treatment (MAT) for opioid use disorder (OUD) is highly efficacious. However, only a fraction of persons with OUD access MAT, and treatment non-adherence and drop out is common. There is a dire need to improve systems to address these issues and to expand the use of MAT for many patients who are out of care. This R44 STTR application responds to RFA-DA-19-020, “HEAL Initiative: America's Startups and Small Businesses Build Technologies to Stop the Opioid Crisis.” It joins an outstanding scientific team at UCLA and a small business that has developed, Opioid Addiction Recovery Support (OARS) -- a software platform that by integrating with the Electronic Health Record (EHR) improves clinical management of patients by primary care providers (PCPs) treating patients with OUD using MAT. OARS platform uses a dashboard to show real-time measurement of patient achievements in recovery. It provides opportunities for patients to interact with their PCPs, allowing for better connection to and support from their PCPs. OARS platform features artificial intelligence to analyze information from the EHR and from patients to provide relapse risk assessment for patients receiving MAT for OUD, an innovation that sets OARS apart from other software solutions. The specific aim of Phase 1 of this STTR Fast Track proposal, is to modify the OARS platform for use in primary care settings by conducting interviews with PCPs (N=20) and their patients with OUD (N=40) in primary care settings to collect data on feasibility and acceptability of engaging with OARS to inform user- centered design of OARS. The specific aims of Phase 2 of this STTR Fast Track proposal are to: (1) employ a “stepped wedge” design to assess the effectiveness of OARS in improving opioid agonist treatment outcomes across 6 treatment programs (N=200 treated patients) and (2) evaluate sustainability and return on investment of OARS implementation across 6 treatment programs. A commercialization plan documents progress to date for OARS platform and presents a market plan to improve both scale-up and quality of MAT services delivered by PCPs in primary care, which is a major contribution to addressing the ongoing opioid epidemic.

项目摘要阿片类药物流行是美国最普遍的行为公共卫生问题，有更多的人使用阿片类药物。 2016 年因吸毒过量死亡人数与艾滋病流行高峰期因艾滋病毒死亡人数相比。然而，药物辅助治疗 (MAT) 对阿片类药物使用障碍 (OUD) 非常有效。部分 OUD 患者接受 MAT，但不遵守治疗和退出治疗的情况很常见。迫切需要改进系统来解决这些问题，并扩大 MAT 对许多患者的使用此 R44 STTR 应用程序响应 RFA-DA-19-020“HEAL Initiative：美国的初创企业”。和小企业开发技术来阻止阿片类药物危机。” 加州大学洛杉矶分校和一家小企业开发了阿片类药物成瘾恢复支持 (OARS)——一款软件通过与电子健康记录 (EHR) 集成改善患者临床管理的平台由初级保健提供者 (PCP) 使用 MAT 平台治疗 OUD 患者。显示患者康复成就的实时测量结果，为患者提供了机会与他们的 PCP 互动，以便更好地连接到他们的 PCP 平台并获得其支持。具有人工智能功能，可分析来自 EHR 和患者的信息，以提供复发风险 MAT for OUD 患者评估，这是 OARS 与其他软件不同的一项创新 STTR 快速通道提案第一阶段的具体目标是修改 OARS 平台。通过对 PCP (N=20) 及其 OUD 患者 (N=40) 进行访谈，在初级保健机构中使用初级保健机构收集有关使用 OARS 的可行性和可接受性的数据，以告知用户 STTR 快速通道提案第二阶段的具体目标是：(1) 采用 “阶梯楔形”设计评估 OARS 在改善阿片类激动剂治疗结果方面的有效性涵盖 6 个治疗方案（N = 200 名接受治疗的患者）以及 (2) 评估可持续性和投资回报商业化计划记录了 6 个治疗项目的 OARS 实施情况。 OARS 平台并提出了一项市场计划，以提高所提供的 MAT 服务的规模和质量初级保健中的 PCP 为解决当前阿片类药物泛滥问题做出了重大贡献。